Variations in use of imaging in a national sample of men with early-stage prostate cancer

被引:32
|
作者
Saigal, CS
Pashos, CL
Henning, JM
Litwin, MS
机构
[1] Univ Calif Los Angeles, Sch Med, Div Urol, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Sch Med, Dept Hlth Sci, Los Angeles, CA 90095 USA
[3] ABT Associates Inc, Clin Trials, Cambridge, MA USA
[4] TAP Pharmaceut Prod Inc, Lake Forest, IL USA
关键词
D O I
10.1016/S0090-4295(01)01543-6
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To measure the national practice variations in imaging studies performed for men newly diagnosed with clinically localized prostate cancer. Methods. We created an analytic file from 1991 to 1996 Medicare claims data using files for a random sample of 5% of all Medicare beneficiaries. Among men with newly diagnosed clinically localized prostate cancer, we identified those undergoing staging bone scans, staging computed tomography (CT), or staging magnetic resonance imaging (MRI) at the time of diagnosis. We conducted univariate and multivariate analyses adjusting for Charlson index score, age group, race, geographic region, and year of diagnosis. Results. In all geographic regions, men receiving radiation therapy (RT) were more likely than those receiving radical prostatectomy (RP) to undergo CT. In the South, RT patients were significantly more likely than RP patients to undergo MRI and bone scans. In the West, RT patients were significantly more likely than RP patients to have bone scans. In multivariate analyses that controlled for all significant univariate findings, treatment with RT significantly predicted for the use of bone scans (odds ratio 1.24, 95% confidence interval 1.17 to 1.31), CT scans (odds ratio 3.26, 95% confidence interval 3.18 to 3.34), and MRI scans (odds ratio 1.47, 95% confidence interval 1.23 to 1.72). Regional differences in the use of imaging technologies for staging persisted in the multivariate analysis. Conclusions. Patients undergoing RT for clinically localized prostate cancer undergo more bone, CT, and MRI scans than do patients undergoing RP, regardless of comorbidity, age, or race. In addition, a significant geographic variation was found in the use of these diagnostic tests. These variations suggest that evidence-based staging guidelines have not been met with broad physician acceptance. UROLOGY 59: 400-404, 2002. (C) 2002 Elsevier Science Inc.
引用
收藏
页码:400 / 404
页数:5
相关论文
共 50 条
  • [21] PERSISTENT NEED FOR SYSTEMATIC BIOPSY FOR MEN ON ACTIVE SURVEILLANCE FOR EARLY-STAGE PROSTATE CANCER
    Fakunle, Mary
    Cowan, Janet
    Washington, Samuel
    Shinohara, Katsuto
    Hao Nguyen
    Cooperberg, Matthew
    Carroll, Peter
    JOURNAL OF UROLOGY, 2023, 209 : E528 - E528
  • [22] Meaningful end points and outcomes in men on active surveillance for early-stage prostate cancer
    Welty, Christopher J.
    Cooperberg, Matthew R.
    Carroll, Peter R.
    CURRENT OPINION IN UROLOGY, 2014, 24 (03) : 288 - 292
  • [23] Racial disparities in the use of radical prostatectomy for early-stage prostate cancer.
    Denberg, TD
    Perez-Stable, EJ
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2002, 17 : 156 - 156
  • [24] Institutional variations in the treatment of early-stage breast cancer
    Nayyar, Apoorve
    Strassle, Paula
    Iles, Kathleen
    Jameison, Danielle
    McGuire, Kandace
    Gallagher, Kristalyn
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : 218 - 219
  • [25] Variations in satisfaction with care and emotional well-being of early-stage prostate cancer patients
    Jayadevappa, R.
    Chhatre, S.
    Wein, A. J.
    Malkowicz, S. B.
    VALUE IN HEALTH, 2006, 9 (06) : A298 - A298
  • [26] Incomplete and inconsistent information provided to men making decisions for treatment of early-stage prostate cancer
    Snow, Stephanie L.
    Panton, Rachel L.
    Butler, Lorna J.
    Wilke, Derek R.
    Rutledge, Robert D. H.
    Bell, David G.
    Rendon, Ricardo A.
    UROLOGY, 2007, 69 (05) : 941 - 945
  • [27] Matching Tumor Risk With Aggressiveness of Treatment in Men With Multiple Comorbidities and Early-Stage Prostate Cancer
    Daskivich, Timothy J.
    Chamie, Karim
    Kwan, Lorna
    Dash, Atreya
    Greenfield, Sheldon
    Litwin, Mark S.
    CANCER, 2013, 119 (19) : 3446 - 3453
  • [28] EBRT less effective for early-stage prostate cancer
    Nelson, Roxanne
    LANCET ONCOLOGY, 2007, 8 (04): : 286 - 286
  • [29] Racial differences in treatment of early-stage prostate cancer
    Richert-Boe, Kathryn E.
    Weinmann, Sheila
    Shapiro, Jean A.
    Rybicki, Benjamin A.
    Enger, Shelley M.
    Van Den Eeden, Stephen K.
    Weiss, Noel S.
    UROLOGY, 2008, 71 (06) : 1172 - 1176
  • [30] WATCHFUL WAITING FOR EARLY-STAGE PROSTATE-CANCER
    JOHANSSON, JE
    UROLOGY, 1994, 43 (02) : 138 - 142